Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Breast Neoplasms 1Blast Crisis 1

Interventions

ruxolitinib 21Azacitidine 5ponatinib 4parsaclisib 4nilotinib 4itacitinib 4anagrelide 3Phlebotomy 3Imatinib Mesylate 3INCB039110 3Aspirin 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2pemigatinib 2luspatercept 2imetelstat 2givinostat hydrochloride 2givinostat 2fedratinib 2asciminib 2INCB057643 2Gemcitabine 2GRN163L peptide 2spartalizumab 1sonidegib 1selinexor 1sabatolimab 1rucaparib 1pembrolizumab 1navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myeloproliferative Disorders × STA 9090 × Clear all
NCT00858572 2014-09-18

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Synta Pharmaceuticals Corp.

Phase 1 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡